




PCT/EP200 4 / 0 1 2 4 2 6

EP041012426



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ



PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

R. Mahoney

Dated

12 November 2004

BEST AVAILABLE COPY

THE PATENT OFFICE
L

- 3 NOV 2003

LONDON

PATENTS • DESIGNS
The Patent Office
COPY • TRADE MARKS

THE PATENT OFFICE
LL

- 4 NOV 2003

LONDON

04NOV03 E649114-5 000192
P01/7700 0.00-0325625.2

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

- 3 NOV 2003

1. Your reference

N.89061 JHS

2. Patent application number

(The Patent Office will fill in this part)

0325625.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ISTITUTO SUPERIORE DI SANITA
VIALE REGINA ELENA 299
00161 ROMA
ITALY

Patents ADP number (*if you know it*)

08691719001

If the applicant is a corporate body, give the country/state of its incorporation

ITALY

4. Title of the invention

NANOPARTICLES FOR DELIVERY OF A
PHARMACOLOGICALLY ACTIVE AGENT

5. Name of your agent (*if you have one*)

J.A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

14 South Square
Gray's Inn
London
WC1R 5JJ

Patents ADP number (*if you know it*)

0026001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)

Date of filing
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

| | |
|-------------|------|
| Description | 44 |
| Claim(s) | 4 |
| Abstract | 2 DL |
| Drawing(s) | 7+7 |

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*) 2 ✓

Request for preliminary examination and search (*Patents Form 9/77*) 1 ✓

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

J.A. Kemp & Co.
J.A. KEMP & CO.

Date 3 November 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Sexton, Jane Helen
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

**NANOPARTICLES FOR DELIVERY OF A PHARMACOLOGICALLY
ACTIVE AGENT**

Field of the invention

5 The present invention relates to core-shell nanoparticles, processes for preparing them, and their use as carriers able to reversibly bind and deliver pharmacologically active substances, in particular nucleic acids, including natural and modified (deoxy)ribonucleotides (DNA, RNA), oligo(deoxy)nucleotides (ODNs) and proteins, into cells.

10

Background of the invention

 DNA vaccines are known to induce immune responses and protective immunity in many animal models of infectious diseases. In human clinical trials, certain DNA vaccines have been shown to induce immune responses, but multiple immunizations of high doses of DNA were required. Therefore, in order to provide protective efficacy in humans, the potency of DNA vaccines needs to be increased.

 During the past decade, new therapeutic approaches introducing genetic materials (such as genes, antisense oligonucleotides and triple-helix-forming oligonucleotides) into intact cells have shown rapid progress both fundamentally and clinically in gene therapy. Many types of synthetic carriers, including liposomes, polymers and polymeric particles have been studied to deliver exogenous genetic materials into cells in a cellular specific or non specific manner. Recently biodegradable or biocompatible polymeric nano-microparticles have been studied as a potential carrier for genetic materials. Advantages of biocompatible polymeric particles as gene delivery carriers include: 1) they are relatively inert and biocompatible; 2) their biological behaviour can be regulated by controlling the size and surface properties; and 3) preparation, storage, and handling are relatively easy. The size and shape of the resulting formulation can also remain homogeneous and uniform, compared to the formulations based on liposomes or polycations.

30 Controlled delivery systems consisting of biocompatible polymers can

potentially protect DNA or proteins from degradation until they are both released and delivered to the desired location at predetermined rates and durations to generate an optimal immune response. The combination of slow release and depot effect may reduce the amount of antigens used in the vaccine and eliminate the booster shots
5 that are necessary for the success of many vaccinations. Moreover, a controlled delivery system can efficiently direct antigens into antigen-presenting cells (APCs) to generate both cellular and humoral responses.

Bertling et al. (Biotechnol. Appl. Biochem. (1991) 13, 390-405) prepared nanoparticles from polycyanoacrylate in the presence of DEAE-dextran. These
10 nanoparticles exhibited a strong DNA binding capacity and resistance against DNase I degradation, although the biological activity of the plasmid DNA was not observed presumably due to the strong binding of the DNA to particles. Poly(alkyl cyanoacrylate) nanoparticles were also evaluated as an oligonucleotide carrier, and their physical stability and biological efficacy of antisense oligonucleotides were
15 found to be greatly enhanced in this formulation (Cortesi et al., Int. J. Pharm. (1994), 105, 181-186; Chavany et al., Pharm. Res. (1994), 11, 1370-1378). Poly(isohexyl cyanoacrylate) nanoparticles were recently used to adsorb cholesterol-oligonucleotide conjugates on their surface via hydrophobic interaction, where a sequence specific antisense effect was observed only when the oligonucleotide was associated with the
20 nanoparticles (Godard et al., Eur. J. Biochem. (1995), 232, 404-410). In the studies mentioned above, the majority of the surface of the particles was probably occupied by poly(oligo)nucleotides and it was difficult to modify the particle surfaces with functional molecules, such as ligand moieties, to modulate biodistribution.

Poly(lactide-co-glycolide) (PLG) microparticles have been intensively studied
25 for vaccine delivery, since the polymer is biodegradable and biocompatible and has been used to develop several drug delivery systems. In addition, PLG microparticles have also been used for a number of years as delivery systems for entrapped vaccine antigens. More recently, PLG microparticles have been described as a delivery system for entrapped DNA vaccines. Nevertheless, recent observations have shown
30 that DNA is damaged during microencapsulation, leading to a significant reduction in

supercoiled DNA. Moreover, the encapsulation efficiency is often low. O'Hagan et al. (Proc. Natl. Acad. Sci. U.S.A. (2000), 97(2), 811-816; Journal of Virology (2001), 75, 9037-9043) first developed a novel approach of adsorbing DNA onto the surface of PLG microparticles to avoid the problems associated with microencapsulation of DNA. Due to the lipophilic nature of the polymer, the addition of hydrophobic cations to the suspension is required to allow DNA binding on the microparticle surface. This approach was shown to increase the potency of DNA vaccines in several animal species, such as guinea pigs and rhesus macaques. However, the hydrophobic cation is not covalently bound to the microparticle surface. Moreover, it exhibits toxicity on cell cultures at the high concentration required. A way to produce charged polymeric microparticles able to adsorb directly protein onto their surface was developed also by O'Hagan et al. (J. Control. Release (2000), 67, 347-356). They prepared anionic microparticles through the inclusion of an anionic detergent, sodium dodecyl sulphate (SDS), in the microparticle preparation process. The anionic microparticles were capable of adsorbing recombinant p-55 gag protein from HIV. Again, the anionic material is not covalently bound to the surface of the microparticle.

Duracher *et al.*, Langmuir (2000) 16, 9002-9008 describe the adsorption of modified HIV-1 capsid p24-protein onto thermosensitive and cationic core-shell poly(styrene)-poly (N-isopropylacrylamide) particles. A two-stop procedure was used to make the particles; in the first step batch polymerisation of styrene and N-isopropylacrylamide (NIPAM) was carried out, and the second step, combining emulsifier-free emulsion and precipitation polymerization, consisted of adding a mixture of NIPAM, amino ethylmethacrylate hydrochloride and, as a cross-linker, methylene bisacrylamide. The shell is cross-linked and in the form of a hydrogel.

Summary of the invention

One of the aims of the present invention is to develop biocompatible polymeric carriers able to reversibly bind and deliver pharmacologically active


substances, such as nucleic acids intact into cells. Another aim of the invention is to develop stealth carriers, able to avoid recognition by the phagocytic cells, and to last longer in the bloodstream.

The present invention accordingly provides core-shell nanoparticles
5 comprising:

- (a) a core which comprises a water insoluble polymer or copolymer, and
- (b) a shell which comprises a hydrophilic polymer or copolymer;

said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble monomer and:

- 10 (i) a monomer of formula (I):




15

wherein

R^1 represents hydrogen or methyl, and

R^2 represents, $-\text{COOAOH}$, $-\text{COO-A-NR}^9\text{R}^{10}$ or $-\text{COO-A-N}^+\text{R}^9\text{R}^{10}\text{R}^{11}\text{X}^-$, in which A represents C_{1-20} alkylene, R^9 , R^{10} and R^{11} each independently represent hydrogen or C_{1-20} alkyl and X represents halogen, sulphate, sulphonate or perchlorate, and
20 a water-soluble polymer of formula (II)



25



wherein

R^3 represents hydrogen or methyl,

R^4 represents hydrogen or C_{1-20} alkyl, and

n is an integer such that the polymer of formula (I) has a number-average molecular
30 weight of at least 1000; or

(ii) a hydrophilic copolymer which comprises repeating units of formulae (III) and (IV):



wherein

R^5 and R^7 each independently represent hydrogen or methyl,
 R^6 represents hydrogen, $-\text{A}-\text{NR}^9\text{R}^{10}$ or $-\text{A}-\text{N}^+\text{R}^9\text{R}^{10}\text{R}^{11}\text{X}^-$, in which A represents C_{1-20} alkylene, R^9 , R^{10} and R^{11} each independently represent hydrogen or C_{1-20} alkyl and X represents halogen, sulphate, sulphonate or perchlorate and
 R^8 represents C_{1-10} alkyl.

The invention further provides:

- a process for preparing the nanoparticles of the invention;
- nanoparticles of the invention which further comprise a pharmacologically active agent, such as a pharmaceutical for therapy or diagnosis, adsorbed at the surface of the nanoparticles (hereinafter described as "pharmacologically active nanoparticles"). Preferably the pharmacologically active agent is an antigen, more preferably a disease-associated antigen. Such nanoparticles are hereinafter described as "antigen-containing nanoparticles";

- a process for preparing the pharmacologically active nanoparticles particularly the antigen-containing nanoparticles of the invention;

- a pharmaceutical composition comprising the pharmacologically

active nanoparticles of the invention;

- a method of generating an immune response in an individual, said method comprising administering the antigen-containing nanoparticles of the invention in a therapeutically effective amount;

5 - a method of preventing or treating HIV infection or AIDS, said method comprising administering the pharmacologically active nanoparticles particularly the antigen-containing nanoparticles of the invention in a therapeutically effective amount;

10 - pharmacologically active nanoparticles particularly the antigen-containing nanoparticles of the invention for use in a method of treatment of the human or animal body by therapy or a diagnostic method practised on the human or animal body;

15 - use of the antigen-containing nanoparticles of the invention for the manufacture of a medicament for generating an immune response in an individual; and

- use of the pharmacologically active nanoparticles particularly the antigen-containing nanoparticles of the invention for the manufacture of a medicament for preventing or treating HIV infection or AIDS.

20 Brief description of the drawings

Figure 1 is a schematic illustration of the structure of a core-shell nanoparticle obtainable by emulsion polymerization of a water insoluble monomer in an aqueous solution comprising a monomer of formula (I) and a polymer of formula (II).

25 Figure 2 is a scanning electron micrograph of nanoparticle sample PEG32 obtained in Example 1.

Figure 3 illustrates ODN adsorption on the nanoparticles obtained in Example 1 as a function of ODN concentration.

Figure 4 illustrates DNA adsorption on nanoparticle sample PEG32 as a function of DNA concentration.

30 Figure 5 provides a comparison between DNA and ODN adsorption ability on

nanoparticle sample PEG32.

Figure 6 illustrates DNA release from nanoparticle sample PEG32.

Figure 7 is a scanning electron micrograph of nanoparticle sample M1 obtained in Example 3.

5

Detailed description of the invention

It is to be understood that this invention is not limited to particular pharmacologically active agents or antigens. It is also to be understood that different applications of the disclosed methods may be tailored to the specific needs in the art.

10 It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

In addition as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a mixture of two or more such antigens, reference to "a nanoparticle" includes reference to mixtures of two or more nanoparticles and vice versa, reference to "a target cell" includes two or more such cells, and the like.

20 All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

The invention provides nanoparticles which may be used for delivering a pharmacologically-active agent, particularly an antigen to target cells. The nanoparticles may have pharmacologically active agent adsorbed or fixed onto their external surface.


25 The nanoparticles of the invention have a core-shell structure, in which the inner core contains a water-insoluble polymer or copolymer. and the outer shell contains a hydrophilic polymer or copolymer. The shell contains functional groups which are charged or ionic or ionisable. Preferably they are ionic or ionisable at physiological pH, for example at a pH in the range from 7.2 to 7.6 and preferably at
30 about 7.4. The nanoparticles are obtainable by emulsion polymerization of a water-

insoluble monomer in an aqueous solution comprising a monomer of formula (I) and a polymer of formula (II), or comprising a hydrophilic copolymer which comprises repeating units of formulae (III) and (IV). The water-insoluble monomer is polymerized to form the core. The shell is formed by the monomer of formula (I) and polymer of formula (II), or by the hydrophilic copolymer which comprises repeating units of formulae (III) and (IV). The external nanoparticle surface is typically a hydrophilic shell that comprises ionic, or ionisable chemical groups. The nanoparticle surface may have an overall positive or negative charge. The nanoparticles preferably have a net positive or negative charge over their entire external surface. The surface charge density typically varies across the surface of the nanoparticles.

The shell and core of the nanoparticles may be composed of a biocompatible and biodegradable polymeric material. The term "biocompatible polymeric material" is defined as a polymeric material which is not toxic to an animal and not carcinogenic. The material is preferably biodegradable in the sense that it should degrade by bodily processes in vivo to products readily disposable by the body and should not accumulate in the body. On the other hand, where the nanoparticles are being inserted into a tissue which is naturally shed by the organism (e.g. sloughing of the skin), the material need not be biodegradable.

The water-insoluble polymer or copolymer used in the core of the nanoparticles of the invention may be any water-insoluble polymer or copolymer obtainable by emulsion polymerization of at least one water-insoluble styrenic, acrylic or methacrylic monomer. Suitable materials include, but are not limited to, polyacrylates, polymethacrylates and polystyrenes and acrylic or methacrylic or styrenic copolymers. When the core comprises a water-insoluble copolymer, the emulsion polymerisation process may use more than one comonomer.

Thus the water-insoluble polymer or copolymer in the core is preferably formed from the polymerization of at least one monomer of formula V



- 5 wherein R^{12} represents hydrogen or methyl
and R^{13} represents phenyl, $-\text{COOR}^{14}$, $-\text{COCN}$ or CN
in which R^{14} is hydrogen or C_{1-20} alkyl

The term "poly(meth)acrylate" as used herein encompasses both polyacrylates
and polymethacrylates. Likewise the term "(meth)acrylate" encompasses both
10 acrylates and methacrylates.

Preferred poly(meth)acrylates which may be used as core materials include
poly(alkyl (meth)acrylates), in particular poly(C_{1-10} alkyl (meth)acrylates), and
preferably poly(C_{1-6} alkyl (meth)acrylates) such as poly(methyl acrylate), poly(methyl
methacrylate), poly(ethyl acrylate), and poly(ethyl methacrylate). Poly(methyl
15 methacrylate) (PMMA) is especially preferred as the core material. PMMA has been
used in surgery for over 50 years and is slowly biodegradable (about 30% to 40% of
the polymer per year) in the form of nanoparticles.

In a first embodiment of the invention, the nanoparticles of the invention are
obtainable by emulsion polymerization of at least one water insoluble monomer in an
20 aqueous solution comprising a monomer of formula (I) and a polymer of formula (II).
The structure of these nanoparticles is shown schematically in Figure 1 of the
accompanying drawings. The shell forms a corona around the core. The corona
structure is able to expand when adsorbing large molecules, such as DNA. The
incorporation of the monomer of formula (I) results in the presence of cationic
25 groups on the surface of the nanoparticles which are able to bind nucleic acids to the
nanoparticle surface. The incorporation of the polymer of formula (II) results in the
presence of poly(ethylene glycol) (PEG) chains in the nanoparticles which produce a
highly hydrophilic outer shell.

R^1 in the monomer of formula (I) is hydrogen or methyl, and is preferably
30 methyl.

R^2 in the monomer of formula (I) may be $-\text{COOAOH}$, $-\text{COO-A-NR}^9\text{R}^{10}$ or $-\text{COO-A-N}^+\text{R}^9\text{R}^{10}\text{R}^{11}\text{X}^-$ and is preferably $-\text{COO-A-NR}^9\text{R}^{10}$ or $-\text{COO-A-N}^+\text{R}^9\text{R}^{10}\text{R}^{11}\text{X}^-$.


A in the monomer of formula (I) is C_{1-20} alkylene and is preferably a C_{1-10} alkylene group, more preferably a C_{1-6} alkylene group, for example a methylene, ethylene, propylene, butylene, pentylene or hexylene group or isomer thereof.
Ethylene is preferred.

R^9 in the monomer of formula (I) is hydrogen or C_{1-20} alkyl, and is preferably a C_{1-20} alkyl group, more preferably a C_{1-10} alkyl group, even more preferably a C_{1-6} alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group, or a pentyl or hexyl group or isomer thereof. Methyl and ethyl are preferred, particularly methyl.

R^{10} in the monomer of formula (I) is hydrogen or C_{1-20} alkyl, and is preferably a C_{1-20} alkyl group, more preferably a C_{1-10} alkyl group, even more preferably a C_{1-6} alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group, or a pentyl or hexyl group or isomer thereof. Methyl and ethyl are preferred, particularly methyl.

R^{11} in the monomer of formula (I) is hydrogen or C_{1-20} alkyl, and is preferably a C_{1-20} alkyl group, more preferably a $\text{C}_4\text{-C}_{16}$ alkyl group, even more preferably a C_{6-10} alkyl group, for example a hexyl, heptyl, octyl, nonyl or decyl group or isomer thereof. n-Octyl is preferred.

An example of a monomer of formula (I) which may be used in the present invention is 2-(dimethyloctyl) ammonium ethyl methacrylate bromine, which has the formula (1) shown below:




5

R³ in the polymer of formula (II) is hydrogen or methyl, and is preferably methyl.

R⁴ in the polymer of formula (II) is hydrogen or C₁₋₂₀ alkyl, and is preferably a C₁₋₂₀ alkyl group, more preferably a C₁₋₁₀ alkyl group, even more preferably a C₁₋₆ alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group, or a pentyl or hexyl group or isomer thereof. Methyl and ethyl are preferred, particularly methyl.

n is an integer such that the polymer of formula (II) has a number-average molecular weight of at least 1000. When the number-average molecular weight of the polymer of formula (II) is at least 1000, it is found that the nanoparticles are able to reversibly bind nucleic acids. When the number-average molecular weight is less than 1000, the nanoparticles have a reduced ability to bind eg. plasmid DNA. For example, it is found that nanoparticles obtained using commercially available poly(ethylene glycol) methyl ether methacrylate having a number-average molecular weight of approximately 350 or approximately 750 bind ODNs but do not bind DNA on the outer shell. In view of the DNA binding ability, the number-average molecular weight of the polymer of formula (II) is preferably 1000 to 6000, more preferably 1500 to 3000, and most preferably 1900 to 2100.

An example of a polymer of formula (II) which may be used in the present invention is poly(ethylene glycol) methyl ether methacrylate having a number-average molecular weight of approximately 2000. A suitable polymer is commercially available from Aldrich, and has the formula (2) shown below:



30

In a second embodiment of the invention, the nanoparticles of the invention are obtainable by emulsion polymerization of a water insoluble monomer in an aqueous solution comprising a hydrophilic polymer which comprises repeating units
5 of formulae (III) and (IV).

R^5 in the repeating unit of formula (III) is hydrogen or methyl.

The preferred values of A, R^9 , R^{10} and R^{11} in the repeating unit of formula (III) are the same as described above for the monomer of formula (I).

R^7 in the repeating unit of formula (IV) is hydrogen or methyl.

10 R^8 in the repeating unit of formula (IV) is C_{1-10} alkyl, and is preferably a C_{1-6} alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group, or a pentyl or hexyl group or isomer thereof. Methyl, ethyl and butyl are preferred.

15 X in the monomer of formula (I) or repeating unit of formula (III) may be a halogen, sulphate, sulphonate or perchlorate. The halogen may be fluorine, chlorine, bromine or iodine, preferably bromine or iodine, most preferably bromine.

An example of a copolymer comprising repeating units of formulae (III) and (IV) which may be used in the present invention is a copolymer of methacrylic acid and ethyl acrylate, for example a statistical copolymer in which the ratio of the free
20 carboxyl groups to the ester groups is approximately 1:1. A suitable copolymer is commercially available from Röhm Pharma under the trade name Eudragit® L 100-55.

A further example of a copolymer comprising repeating units of formulae (III) and (IV) which may be used in the present invention is a copolymer of 2-
25 (dimethylamino)ethyl methacrylate and C_{1-6} alkyl methacrylate, for example a copolymer of 2-(dimethylamino)ethyl methacrylate, methyl methacrylate and butyl methacrylate. A suitable copolymer is commercially available from Röhm Pharma under the trade name Eudragit® E 100.

The present invention provides a new polymeric delivery system for
30 pharmacologically active substances such as nucleic acids based on polymeric

nanoparticles with a core-shell structure and a tailored surface. The inner core is mainly constituted of a water-insoluble polymer or copolymer such as poly(methylmethacrylate) and the hydrophilic outer shell is constituted by hydrosoluble copolymers bearing ionic or ionisable functional groups. For example, the cationic polymers are able to reversibly bind ODNs and DNA. The anionic polymers are able to reversibly bind, protect and deliver basic proteins such as Tat. Additionally, the nanoparticles may comprise PEG chain brushes which increase the biocompatibility. It is found that the nanoparticles of the first embodiment of the invention are able to bind relatively high amounts of plasmid PCV₀ - tat DNA (5-6% w/w) and to release them with distinct kinetic pathways.

The PEG-based shell in the nanoparticles of the first embodiment of the invention prevents, or at least reduces, the nanoparticle clearance from the body by the phagocytic cells of the reticuloendothelial system (RES). In fact, the capture of foreign nanoparticles is believed to be initially mediated by the adsorption of plasma proteins (opsonins), leading to recognition by the phagocytic cells. The hydrophilicity of the PEG chains located at the nanoparticle surface is responsible for both particle surface steric stabilization and induction of dysopsonic effect, masking the presence of the carriers from the recognition of RES. By avoiding opsonization, polymeric nanoparticles can overcome removal by the mononuclear phagocyte system, thus achieving the goal of having a slow-constant release of drug in the circulation for extended periods of time and improving drug pharmacokinetic performances.

The nanoparticles of the invention are able to reversibly bind and deliver pharmacologically active substances, particularly nucleic acids such as DNA, ODNs and proteins, into cells. Binding on the outer shell is desirable because it prevents degradation of the pharmacologically active substance and allows its release, in the biologically active form, both in vitro and in vivo.

These nanoparticles of the invention are synthesized by emulsion polymerization employing functionalised comonomers as emulsion stabilizers. Emulsion polymerization systems without regular emulsifiers are well known

(Gilbert et al., Emulsion Polymerization, A Mechanistic Approach, Academic Press: London, 1995; Wu et al., Macromolecules (1997), 30, 2187; Liu et al., Langmuir (1997), 13, 4988; Schoonbrood et al., Macromolecules (1997), 30, 6024; Cochin et al., Macromolecules (1997), 30, 2287-2287; Xu et al., Langmuir (2001), 17, 6077-6085; Delair et al., Colloid Polym. Sci. (1994), 272, 962), and essentially involve one reactive component, namely "surfmr" or "polymerizable surfactant" which acts to stabilize the emulsion recipe.

As reported in many emulsion polymerization systems including water soluble comonomers (Gilbert et al., Emulsion Polymerization, A Mechanistic Approach, Academic Press: London, 1995; Delair et al., Colloid Polym. Sci. (1994), 272, 962), the complex particle forming mechanism involves homogeneous nucleation. The reaction starts in the aqueous phase leading to the formation of water-soluble oligoradicals, rich in the water soluble comonomer, until they reach the limit of solubility and precipitate to form primary particles which are able to growth by incorporation of the monomer and comonomer. The water soluble units are preferentially located at the nanoparticle surface and actively participate to the latex stabilization. In this way, nanoparticles can be obtained with a tailored surface dictated by the chemical structure of the employed comonomer.

In the emulsion polymerization process to prepare nanoparticles of the present invention the monomers and, if present, polymers are preferably mixed together before emulsion polymerization takes place. This allows production of the core-shell structure of the nanoparticles with the shell forming a corona around the core as shown in Figure 1.

Specifically, the nanoparticles of the invention may be prepared by emulsion polymerization of a water-insoluble monomer in an aqueous solution comprising:

- (i) a monomer of formula (I) and a polymer of formula (II), or
- (ii) a hydrophilic copolymer which comprises repeating units of formulae (III) and (IV).

The polymerization reaction is typically carried out by introducing the water-insoluble monomer, preferably dropwise, into an aqueous solution comprising the

monomer of formula (I) and the polymer of formula (II), or comprising the hydrophilic copolymer which comprises repeating units of formulae (III) and (IV). The reaction is preferably carried out under an inert atmosphere, such as nitrogen, preferably with constant stirring. The aqueous solution may comprise a further solvent, such as acetone. For example a 90/10 vol% water/acetone mixture may be used.

Following addition of the water-insoluble monomer, the system is preferably left to stabilize for a time, e.g. for 10 to 60 minutes, preferably 15 to 40 minutes, prior to addition of a free radical initiator. Examples of suitable free radical initiators include anionic potassium persulfate (KPS), ammonium persulphate and cationic 2,2'-azobis(2-methylpropionamidine) dihydrochloride (AIBA). The free radical initiator is typically added in the form of an aqueous solution.

Polymerization is typically performed at a temperature of 50 to 100°C, preferably 65 to 85°C, for at least 90 minutes. In some cases, the reaction may take as long as 20 hours or more.


At the end of the reaction, the product may be purified by known methods. For example, the product may be filtered and purified by repeated dialysis, e.g. ten times or more against an aqueous solution of cetyl trimethyl ammonium bromide, and then ten times or more against water.

Following the isolation of the nanoparticles from the emulsion, the nanoparticles may be dried by exposure to air or by other conventional drying techniques such as lyophilization, vacuum drying, drying over a desiccant, or the like. Prior to adsorption of a pharmacologically active agent, the nanoparticles may be redispersed in a suitable liquid and temporarily stored. The skilled person will recognise under what conditions the nanoparticles of the invention may be stored. Typically, the nanoparticles are stored at a low temperature, for example about 4°C.

The nanoparticles usually have a spherical shape, although irregularly-shaped nanoparticles are possible. When viewed under a microscope, therefore, the nanoparticles are typically spheroidal but may be elliptical, irregular in shape or toroidal. In certain embodiments the nanoparticles have a raspberry-like

morphology, as shown in Figure 2.

The starting materials of formulae (I), (II), (III) and (IV) are commercially available or may be prepared by known methods. For example, a monomer of formula (I) in which R^2 represents $-A-N^+R^9R^{10}R^{11}X^-$ may be prepared by reacting a
5 compound of formula (VI):



with a compound of formula $R^{11}X$.

10 The nanoparticles of the invention generally have a number-average particle diameter measured by scanning electron microscopy of less than 1100 nm, preferably 50 to 1000nm more preferably 50 to 500 nm, e.g. 50 to 300 nm. It is found that the particle diameter is dependent on the free radical initiator that is used during the synthesis of the nanoparticles. For example, samples obtained using AIBA as the
15 free radical initiator generally have a lower number-average particle diameter than samples obtained using KPS. Size reduction is advantageous because it means that a greater surface area is available for adsorption of pharmacologically active substances, thus reducing the amount of polymer required to be administered.


The particle size can be measured using conventional techniques such as
20 microscopic techniques (where particles are sized directly and individually rather than grouped statistically), absorption of gasses, or permeability techniques. If desired, automatic particle-size counters can be used (for example, the Coulter Counter, HIAC Counter, or Gelman Automatic Particle Counter) to ascertain average particle size.

25 Actual nanoparticle density can be readily ascertained using known quantification techniques such as helium pycnometry and the like. Alternatively, envelope ("tap") density measurements can be used to assess the density of a particulate composition. Envelope density information is particularly useful in characterizing the density of objects of irregular size and shape. Envelope density, or
30 "bulk density," is the mass of an object divided by its volume, where the volume

includes that of its pores and small cavities. Other, indirect methods are available which correlate to density of individual particles. A number of methods of determining envelope density are known in the art, including wax immersion, mercury displacement, water absorption and apparent specific gravity techniques. A number of suitable devices are also available for determining envelope density, for example, the GeoPyc™ Model 1360, available from the Micromeritics Instrument Corp. The difference between the absolute density and envelope density of a sample pharmaceutical composition provides information about the sample's percentage total porosity and specific pore volume.

Nanoparticle morphology, particularly the shape of a particle, can be readily assessed using standard light or electron microscopy. It is preferred that the particles have a spherical or at least substantially spherical shape. It is also preferred that the particles have an axis ratio of 2 or less, i.e. from 2:1 to 1:1, to avoid the presence of rod- or needle-shaped particles. These same microscopic techniques can also be used to assess the particle surface characteristics, for example, the amount and extent of surface voids or degree of porosity.

The nanoparticles of the invention may also comprise a fluorescent chromophore. For example, yellow-green fluorescent nanoparticles may be obtained by adding the fluorescein-based allylic monomer (3):



to the polymerization reaction mixture during synthesis of the nanoparticles. The fluorescent monomer (3) is able to polymerize under the employed reaction conditions to give fluorescent nanoparticles. The preparation procedure for these nanoparticles allows the highly fluorescent hydrophobic chromophore to be

incorporated into the nanoparticle core. The covalent binding of the dye molecule yields nanoparticles with high fluorescence intensity, minimal quenching and good photostability, so that exposure to light does not reduce their photoemission.

Nanoparticles comprising a fluorescent chromophore may be used as probes
5 in order to get information concerning the core-shell nanoparticle uptake in cellular systems and in vivo.

The nanoparticles of the invention may have pharmacologically-active agent adsorbed at their surface. The term "adsorbed" or "fixed" means that the pharmacologically-active agent is attached to the external surface of the shell of the
10 nanoparticle. The adsorption or fixation preferably occurs by electrostatic attraction. Electrostatic attraction is the attraction or bonding generated between two or more oppositely charged or ionic chemical groups. The adsorption or fixation is typically reversible.

The pharmacologically-active agent preferably has a net charge that attracts it
15 to the ionic or ionisable hydrophilic shell of the nanoparticle. The pharmacologically-active agent typically has one or more charged chemical or ionic groups. In the case of the pharmacologically-active agent being a peptide, the pharmacologically-active agent typically has one or more charged amino acid residues. The pharmacologically-active agent typically has a net positive or negative
20 charge. The pharmacologically-active agent preferably has a net charge that is opposite to the charge of the hydrophilic shell of the nanoparticle.

The pharmacologically-active agent may be adsorbed onto the nanoparticles by mixing a solution of the pharmacologically-active agent with a liquid suspension of the nanoparticles. The pharmacologically-active agent and nanoparticles are
25 typically mixed in a suitable liquid, for example a physiological buffer such as phosphate buffered saline (PBS). The mixture may be left for some time under conditions suitable for the preservation of the pharmacologically-active agent and formation of the bond between the pharmacologically-active agent and nanoparticles. These conditions will be recognised by a person skilled in the art. Adsorption is
30 usually carried out at a temperature of from 0°C to 37°C, preferably from 4°C to

25°C. Adsorption may take place in the dark. Adsorption is typically carried out for from 30 and 180 minutes. Following adsorption, the nanoparticles of the invention may be separated from the adsorption liquid by methods known in the art, for example centrifugation. The nanoparticles may then be resuspended in a liquid
5 suitable for administration to an individual.

Pharmacologically-Active Agents useful in the Invention

A "pharmacologically-active agent" includes any compound or composition of matter which, when administered to an organism (human or animal subject) induces a desired pharmacologic and/or physiologic effect by local and/or systemic
10 action. The term therefore encompasses those compounds or chemicals traditionally regarded as drugs, biopharmaceuticals (including molecules such as peptides, proteins, nucleic acids), vaccines and gene therapies (e.g., gene constructs).

Pharmacologically-active agents useful in this invention include drugs acting at synaptic and neuroeffector junctional sites (cholinergic agonists, anticholinesterase
15 agents, atropine, scopolamine, and related antimuscarinic drugs, catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists); drugs acting on the central nervous systems; autacoids (drug therapy of inflammation); drugs affecting renal function and electrolyte metabolism; cardiovascular drugs; drugs affecting gastrointestinal function; chemotherapy of neoplastic diseases; drugs acting on the
20 blood and the blood-forming organs; and hormones and hormone antagonists. Thus, the agents useful in the invention include, but are not limited to anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; local and general anesthetics; anorexics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antihistamines; anti-inflammatory agents; antinauseants; antimigrane
25 agents; antineoplastics; antipruritics; antipsychotics; antipyretics; antispasmodics; cardiovascular preparations (including calcium channel blockers, beta-blockers, beta-agonists and antiarrhythmics); antihypertensives; diuretics; vasodilators; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones; bone growth stimulants and bone resorption inhibitors;
30 immunosuppressives; muscle relaxants; psychostimulants; sedatives; tranquilizers;

proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced); and nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including double- and single-stranded molecules and supercoiled or condensed molecules, gene constructs, expression vectors, plasmids, antisense molecules and the like.

Specific examples of drugs useful in this invention include angiotensin converting enzyme (ACE) inhibitors, β -lactam antibiotics and γ -aminobutyric acid (GABA)-like compounds. Representative ACE inhibitors are discussed in Goodman and Gilman, Eighth Edition at pp. 757-762, which is incorporated herein by reference. These include quinapril, ramipril, captopril, benazepril, fosinopril, lisinopril, enalapril, and the like and the respective pharmaceutically acceptable salts thereof. Beta-lactam antibiotics are those characterized generally by the presence of a beta-lactam ring in the structure of the antibiotic substance and are discussed in Goodman and Gilman, Eighth Edition at pp. 1065 to 1097, which is incorporated herein by reference. These include penicillin and its derivatives such as amoxicillin and cephalosporins. GABA-like compounds may also be found in Goodman and Gilman. Other compounds include calcium channel blockers (e.g., verapamil, nifedipine, nicardipine, nimodipine and diltiazem); bronchodilators such as theophylline; appetite suppressants, such as phenylpropanolamine hydrochloride; antitussives, such as dextromethorphan and its hydrobromide, noscapine, carbetapentane citrate, and chlorphedianol hydrochloride; antihistamines, such as terfenadine, phenidamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants, such as phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, chlorpheniramine hydrochloride, pseudoephedrine hydrochloride, chlorpheniramine maleate, ephedrine, phenylephrine, chlorpheniramine, pyrilamine, phenylpropanolamine, dexchlorpheniramine, phenyltoxamine, phenindamine, oxymetazoline, methscopalamine, pseudoephedrine, brompheniramine, carbinoxamine and their pharmaceutically acceptable salts such as the hydrochloride,

maleate, tannate and the like, β -adrenergic receptor antagonists (such as propanolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esniolol, and acebutolol); narcotic analgesics such as morphine; central nervous system (CNS) stimulants such as methylphenidate hydrochloride; antipsychotics or psychotropics such as phenothiazines, tricyclic antidepressants and MAO inhibitors; benzodiazepines such as alprozolam, diazepam; and the like; and certain non steroidal antiinflammatory drugs (NSAIDs), (e.g., salicylates, pyrazolons, indomethacin, sulindac, the fenamates, tolmetin, propionic acid derivatives) such as salicylic acid, aspirin, methyl salicylate, diflunisal, salsalate, phenylbutazone, indomethacin, oxyphenbutazone, apazone, mefenamic acid, meclofenamate sodium, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, piroxicam, diclofenac, etodolac, ketorolac, aceclofenac, nabumetone, and the like; protease inhibitors, particularly HIV protease inhibitors such as saquinavir, ritonavir, amprenavir, indinavir, lopinavir and nelfinavir.

Another pharmacologically-active agent useful in the invention is an antigen, i.e., molecule which contains one or more epitopes that will stimulate a host's immune system to make a cellular antigen-specific immune response, or a humoral antibody response. Thus, antigens include proteins, polypeptides, antigenic protein fragments, oligosaccharides, polysaccharides, and the like. The antigen can be derived from any known virus, bacterium, parasite, plants, protozoans, or fungus, and can be a whole organism or immunogenic parts thereof, e.g., cell wall components. An antigen can also be derived from a tumor. An oligonucleotide or polynucleotide which expresses an antigen, such as in DNA immunization applications, is also included in the definition of antigen. Synthetic antigens are also included in the definition of antigen, for example, haptens, polypeptides, flanking epitopes, and other recombinant or recombinant or synthetically derived antigens (Bergmann *et al* (1993) *Eur. J. Immunol.* 23:2777-2781; Bergmann *et al* (1996) *J. Immunol.* 157:3242-3249; Suhrbier, A. (1997) *Immunol. And Cell Biol.* 75:402-408; Gardner *et al* (1998) 12th World AIDS Conference, Geneva, Switzerland (June 28 – July 3, 1998).

The antigen is preferably a disease-associated antigen. Thus, a

disease-associated antigen is a molecule which contains epitopes that will stimulate a host's immune system to make a cellular antigen-specific immune response, and/or a humoral antibody response against the disease. The disease-associated antigen may therefore be used for prophylactic or therapeutic purposes.

- 5 Antigens for use in the invention include, but are not limited to, those containing, or derived from, members of the families Picornaviridae (for example, polioviruses, etc.); Caliciviridae; Togaviridae (for example, rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae; Reoviridae; Birnaviridae; Rhabdoviridae (for example, rabies virus, measles virus, respiratory syncytial virus, etc.);
- 10 Orthomyxoviridae (for example, influenza virus types A, B and C, etc.); Bunyaviridae; Arenaviridae; Retroviridae (for example, HTLV-I; HTLV-II; HIV-1; and HIV-2); simian immunodeficiency virus (SIV) among others. Additionally, viral antigens may be derived from a papilloma virus (for example, HPV); a herpes virus, i.e. herpes simplex 1 and 2; a hepatitis virus, for example, hepatitis A virus (HAV),
- 15 hepatitis B virus (HBV), hepatitis C virus (HCV), the delta hepatitis D virus (HDV), hepatitis E virus (HEV) and hepatitis G virus (HGV) and the tick-borne encephalitis viruses; smallpox, parainfluenza, varicella-zoster, cytomegalavirus, Epstein-Barr, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps, rubella, coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever, Rift
- 20 Valley fever, lymphocytic choriomeningitis, and the like. See for example, Virology, 3rd Edition (W.K. Joklik ed. 1988); *Fundamental Virology*, 2nd Edition (B.N. Fields and D.M. Knipe, eds. 1991), for a description of these and other viruses.

- Bacterial antigens include, but are not limited to, those containing or derived from organisms that cause diphtheria, cholera, tuberculosis, tetanus, pertussis,
- 25 meningitis, and other pathogenic states, including *Meningococcus* A, B and C, *Hemophilus influenza* type B (HIB), and *Helicobacter pylori*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Streptococcus pyrogenes*, *Corynebacterium diphtheriae*, *Listeria monocytogenes*, *Bacillus anthracis*, *Clostridium tetani*, *Clostridium botulinum*, *Clostridium perfringens*, *Neisseria meningitidis*, *Neisseria*
- 30 gonorrhoeae, *Streptococcus mutans*, *Pseudomonas aeruginosa*, *Salmonella typhi*,

Haemophilus parainfluenzae, *Bordetella pertussis*, *Francisella tularensis*, *Yersinia pestis*, *Vibrio cholerae*, *Legionella pneumophila*, *Mycobacterium tuberculosis*, *Mycobacterium leprae*, *Treponema pallidum*, *Leptospira interrogans*, *Borrelia burgdorferi*, *Campylobacter jejuni*, and the like.

- 5 Examples of anti-parasitic antigens include those derived from organisms causing malaria and Lyme disease. Antigens of such fungal, protozoan, and parasitic organisms such as *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Candida albicans*, *Candida tropicalis*, *Nocardia asteroides*, *Rickettsia rickettsii*, *Rickettsia typhi*, *Mycoplasma pneumoniae*, *Chlamydia psittaci*, *Chlamydia trachomatis*,
10 *Plasmodium falciparum*, *Trypanosoma brucei*, *Entamoeba histolytica*, *Toxoplasma gondii*, *Trichomonas vaginalis*, *Schistosoma mansoni*, and the like.

In an especially preferred embodiment, the antigen adsorbed on the nanoparticle is the full length HIV Tat protein or an immunogenic fragment thereof, tat DNA or other DNA or protein which is an HIV antigen.

- 15 The disease-associated antigen may be cancer-associated. A cancer-associated antigen is a molecule which contains epitopes that will stimulate a host's immune system to make a cellular antigen-specific immune response, and/or a humoral antibody response against the cancer. A cancer-associated antigen is typically found in the body of an individual when that individual has cancer. A
20 cancer-associated antigen is preferably derived from a tumour. Cancer-associated antigens include, but are not limited to, cancer-associated antigens (CAA), for example, CAA-breast, CAA-ovarian and CAA-pancreatic; the melanocyte differentiation antigens, for example, Melan A/MART-1, tyrosinase and gp100; cancer-germ cell (CG) antigens, for example, MAGE and NY-ESO-1; mutational
25 antigens, for example, MUM-1, p53 and CDK-4; over-expressed self-antigens, for example, p53 and HER2/NEU and tumour proteins derived from non-primary open reading frame mRNA sequences, for example, LAGE1.

- The antigen or immunogenic fragments of antigens mentioned herein typically comprise one or more T cell epitopes. "T cell epitopes" are generally those
30 features of a peptide structure capable of inducing a T cell response. In this regard, it

is accepted in the art that T cell epitopes comprise linear peptide determinants that assume extended conformations within the peptide-binding cleft of MHC molecules, (Unanue et al. (1987) Science 236: 551-557). As used herein, a T cell epitope is generally a peptide having about 8-15, preferably 5-10 or more amino acid residues.

5 The nanoparticles of the invention can be viewed as a "vaccine composition" and as such include any pharmaceutical composition which contains an antigen and which can be used to prevent or treat a disease or condition in a subject. The term encompasses both subunit vaccines, i.e., vaccine compositions containing antigens which are separate and discrete from a whole organism with which the antigen is
10 associated in nature, as well as compositions containing whole killed, attenuated or inactivated bacteria, viruses, parasites or other microbes. The vaccine can also comprise a cytokine that may further improve the effectiveness of the vaccine.

Suitable nucleotide sequences for use in the present invention include any therapeutically relevant nucleotide sequence. Thus, the present invention can be used
15 to deliver one or more genes encoding a protein defective or missing from a target cell genome or one or more genes that encode a non-native protein having a desired biological or therapeutic effect (e.g., an antiviral function) or a sequence that corresponds to a molecule having an antisense or ribozyme function. The invention can also be used to deliver a nucleotide sequence capable of providing immunity, for
20 example an immunogenic sequence that serves to elicit a humoral and/or cellular response in a subject.

Suitable genes which can be delivered include those used for the treatment of inflammatory diseases, autoimmune, chronic and infectious diseases, including such disorders as AIDS, cancer, neurological diseases, cardiovascular disease,
25 hypercholesterolemia; various blood disorders including various anemias, thalassemia and hemophilia; genetic defects such as cystic fibrosis, Gaucher's Disease, adenosine deaminase (ADA) deficiency, emphysema, etc. A number of antisense oligonucleotides (e.g., short oligonucleotides complementary to sequences around the translational initiation site (AUG codon) of an mRNA) that are useful in antisense
30 therapy for cancer and for viral diseases have been described in the art. See, e.g.,

Han *et al* 1991) *Proc. Natl. Acad. Sci. USA* 88:4313; Uhlmann *et al* (1990) *Chem. Rev.* 90:543; Helene *et al* (1990) *Biochim. Biophys. Acta.* 1049:99; Agarwal *et al* (1988) *Proc. Natl. Acad. Sci. USA* 85:7079; and Heikkila *et al* (1987) *Nature* 328:445. A number of ribozymes suitable for use herein have also been described.

- 5 See, e.g., Chec *et al* (1992) *J. Biol. Chem.* 267:17479 and U.S. Patent No. 5,225,347 to Goldberg *et al*.

For example, in methods for the treatment of solid tumors, genes encoding toxic peptides (i.e., chemotherapeutic agents such as ricin, diphtheria toxin and cobra venom factor), tumor suppressor genes such as p53, genes coding for mRNA
10 sequences which are antisense to transforming oncogenes, antineoplastic peptides such as tumor necrosis factor (TNF) and other cytokines, or transdominant negative mutants of transforming oncogenes, can be delivered for expression at or near the tumor site.

Similarly, genes coding for peptides known to display antiviral and/or
15 antibacterial activity, or stimulate the host's immune system, can also be administered. Thus, genes encoding many of the various cytokines (or functional fragments thereof); such as the interleukins, interferons and colony stimulating factors, will find use with the instant invention. The gene sequences for a number of these substances are known.

20 For the treatment of genetic disorders, functional genes corresponding to genes known to be deficient in the particular disorder can be administered to the subject. The instant invention will also find use in antisense therapy, e.g., for the delivery of oligonucleotides able to hybridize to specific complementary sequences thereby inhibiting the transcription and/or translation of these sequences. Thus DNA
25 or RNA coding for proteins necessary for the progress of a particular disease can be targeted, thereby disrupting the disease process. Antisense therapy, and numerous oligonucleotides which are capable of binding specifically and predictably to certain nucleic acid target sequences in order to inhibit or modulate the expression of disease-causing genes are known and readily available to the skilled practitioner.
30 Uhlmann *et al* (1990) *Chem Rev.* 90:543, Neckers *et al* (1992) *Crit. Rev.*

Oncogenesis 3:175; Simons *et al* (1992) *Nature* 359:67; Bayever *et al* (1992) *Antisense Res. Dev.* 2:109; Whitesell *et al* (1991) *Antisense Res. Dev.* 1:343; Cook *et al* (1991) *Anti-cancer Drug Design* 6:585; Eguchi *et al* (1991) *Annu. Rev. Biochem.* 60:631. Accordingly, antisense oligonucleotides capable of selectively binding to
5 target sequences in host cells are provided herein for use in antisense therapeutics.

The nanoparticles of the invention can comprise from about 0.01 to about 99% of the antigen by weight, for example from about 0.01 to 10%, typically 2 to 8% e.g. 5 to 6% by weight. The actual amount depends on a number of factors including the nature of the pharmacologically-active agent, the dose desired and other variables
10 readily appreciated by those skilled in the art.

When the pharmacologically active agent is an antigen, administration of nanoparticles of the invention generates an immune response in an individual. Adsorption of the antigen to the external surface of the nanoparticle preserves the biological activity of the antigen; adsorption of the antigen to the nanoparticle does
15 not affect the immunogenicity of the antigen. Adsorption of the antigen to the nanoparticle reduces the amount of antigen required to generate an immune response, eliminates or reduces the number of antigen booster shots needed and improves the handling or shelf-life of the antigen.

When the pharmacologically active agent is a drug, biopharmaceutical or
20 gene therapy, administration of nanoparticles of the invention prevents or ameliorates a disease or condition in the man or animal being treated, or assists in the diagnosis of such disease or condition.

Accordingly, the present invention also relates to prophylactic or therapeutic methods utilising the nanoparticles of the invention. When the pharmacologically-
25 active agent is an antigen these prophylactic or therapeutic methods involve generating an immune response in an individual using the nanoparticles of the invention. Thus, the nanoparticles of the invention may be administered to an individual to generate an immune response in that individual. Alternatively, the nanoparticles may be used in the manufacture of a medicament for diagnosing,
30 treating or preventing a condition in an individual particularly generating an immune

response in an individual.

The term "administer" or "deliver" is intended to refer to any delivery method of contacting the nanoparticles with the target cells or tissue. The term "tissue" refers to the soft tissues of an animal, patient, subject etc as defined herein, which term
5 includes, but is not limited to, skin, mucosal tissue (eg. buccal, conjunctival, gums), vaginal and the like. Bone may however be treated too by the particles of the invention, for example bone fractures.

When administration is for the purpose of treatment, administration may be either for prophylactic or therapeutic purpose. When provided prophylactically, the
10 pharmacologically-active agent is provided in advance of any symptom. The prophylactic administration of the pharmacologically-active agent serves to prevent or attenuate any subsequent symptom. When provided therapeutically the pharmacologically-active agent is provided at (or shortly after) the onset of a symptom. The therapeutic administration of the pharmacologically-active agent
15 serves to attenuate any actual symptom. Administration and therefore the methods of the invention may be carried out *in vivo* or *in vitro*.

The terms "animal", "individual", "patient" and "subject" are used interchangeably herein to refer to a subset of organisms which include any member of the subphylum cordata, including, without limitation, humans and other primates,
20 including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as bovine animals, for example cattle; ovine animals, for example sheep; porcine, for example pigs; rabbit, goats and horses; domestic mammals such as dogs and cats; wild animals; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds
25 such as chickens, turkeys and other gallinaceous birds, ducks, geese; and the like. The terms do not denote a particular age. Thus, both adult and newborn individuals are intended to be covered. In one embodiment, the individual is typically capable of being infected by HIV.

The invention includes a method of diagnosing, treating or preventing a
30 condition in a subject by administering the nanoparticles described herein to a subject

in need of such treatment. As used herein, the term "treatment" or "treating" includes any of the following: the prevention of infection or reinfection; the reduction or elimination of symptoms; and the reduction or complete elimination of a pathogen. Treatment may be effected prophylactically (prior to infection) or therapeutically
5 (following infection). The methods of this invention also include effecting a change in an organism by administering the nanoparticles.

The methods of the invention may be carried out on individuals at risk of disease associated with antigen. Typically, the methods of the invention are carried out on individuals at risk of microbial infection or cancer associated with or caused
10 by the antigen. In a preferred embodiment, the method of the invention is carried out on individuals at risk of infection with HIV or developing AIDS.

The methods described herein elicit an immune response against particular antigens for the treatment and/or prevention of a disease and/or any condition which is caused by or exacerbated by the disease. The methods described herein typically
15 elicit an immune response against particular antigens for the treatment and/or prevention of microbial infection or cancer and/or any condition which is caused by or exacerbated by microbial infection or cancer. In a particular embodiment, the methods described herein elicit an immune response against particular antigens for the treatment and/or prevention of HIV infection and/or any condition which is
20 caused by or exacerbated by HIV infection, such as AIDS.

The method of the invention may be carried out for the purpose of stimulating a suitable immune response. By suitable immune response, it is meant that the method can bring about in an immunized subject an immune response characterized by the increased production of antibodies and/or production of B and/or T
25 lymphocytes specific for an antigen, wherein the immune response can protect the subject against subsequent infection. In a preferred embodiment, the method can bring about in an immunized subject an immune response characterized by the increased production of antibodies and/or production of B and/or T lymphocytes specific for HIV-1 Tat, wherein the immune response can protect the subject against
30 subsequent infection with homologous or heterologous strains of HIV, reduce viral

burden, bring about resolution of infection in a shorter amount of time relative to a non-immunized subject, or prevent or reduce clinical manifestation of disease symptoms, such as AIDS symptoms.

The aim of this embodiment of the invention is to generate an immune response in an individual. Preferably, antibodies to the antigen are generated in the individual. Preferably IgG, IgA or IgM antibodies to the antigen are generated. Antibody responses may be measured using standard assays such as radioimmunoassay, ELISAs, and the like, well known in the art.

Preferably cell-mediated immunity is generated, and in particular a CD8 T cell response generated. In this case the administration of the nanoparticles may, for example increase the level of antigen experienced CD8 T cells. The CD8 T cell response may be measured using any suitable assay (and thus may be capable of being detected in such an assay), such as an ELISPOT assay, preferably an IFN- γ ELISPOT assay, a CTL assay or peptide proliferation assay. Preferably, a CD4 T cell response is also generated, such as the CD4 Th1 response. Thus the levels of antigen experienced CD4 T cells may also be increased. Such increased levels of CD4 T cells may be detected using a suitable assay, such as a proliferation assay.

The invention further provides the pharmacologically-active nanoparticles of the invention in a pharmaceutical composition which also includes a pharmaceutically acceptable excipient. Such an "excipient" generally refers to a substantially inert material that is nontoxic and does not interact with other components of the composition in a deleterious manner.

These excipients, vehicles and auxiliary substances are generally pharmaceutical agents that do not themselves induce an immune response in the individual receiving the composition, and which may be administered without undue toxicity.

Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethylene glycol, hyaluronic acid, glycerol and ethanol. Pharmaceutically acceptable salts can be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and

the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.

It is also preferred, although not required, that a pharmaceutical composition comprising pharmacologically-active nanoparticles will contain a pharmaceutically acceptable carrier that serves as a stabilizer, particularly for peptides, or proteins or the like. Examples of suitable carriers that also act as stabilizers for peptides include, without limitation, pharmaceutical grades of dextrose, sucrose, lactose, trehalose, mannitol, sorbitol, inositol, dextran, and the like. Other suitable carriers include, again without limitation, starch, cellulose, sodium or calcium phosphates, citric acid, tartaric acid, glycine, high molecular weight polyethylene glycols (PEGs), and combination thereof. It may also be useful to employ a charged lipid and/or detergent. Suitable charged lipids include, without limitation, phosphatidylcholines (lecithin), and the like. Detergents will typically be a nonionic, anionic, cationic or amphoteric surfactant. Examples of suitable surfactants include, for example, Tergitol® and Triton® surfactants (Union Carbide Chemicals and Plastics, Danbury, CT), polyoxyethylenesorbitans, for example, TWEEN® surfactants (Atlas Chemical Industries, Wilmington, DE), polyoxyethylene ethers, for example Brij, pharmaceutically acceptable fatty acid esters, for example, lauryl sulfate and salts thereof (SDS), and like materials.

A thorough discussion of pharmaceutically acceptable excipients, carriers, stabilizers and other auxiliary substances is available in REMINGTONS PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991), incorporated herein by reference.

In order to augment an immune response in a subject, the compositions and methods described herein can further include ancillary substances/adjuvants, such as pharmacological agents, cytokines, or the like. Suitable adjuvants include any substance that enhances the immune response of the subject to the antigens attached to the nanoparticles of the invention. They may enhance the immune response by affecting any number of pathways, for example, by stabilizing the antigen/MHC complex, by causing more antigen/MHC complex to be present on the cell surface,

by enhancing maturation of APCs, or by prolonging the life of APCs (e.g., inhibiting apoptosis).

Typically adjuvants are co-administered with the vaccine or nanoparticle. As used herein the term "adjuvant" refers to any material that enhances the action of an antigen or the like.

Thus, one example of an adjuvant is a "cytokine." As used herein, the term "cytokine" refers to any one of the numerous factors that exert a variety of effects on cells, for example, inducing growth, proliferation or maturation. Certain cytokines, for example TRANCE, flt-3L, and CD40L, enhance the immunostimulatory capacity of APCs. Non-limiting examples of cytokines which may be used alone or in combination include, interleukin-2 (IL-2), stem cell factor (SCF), interleukin 3 (IL-3), interleukin 6 (IL-6), interleukin 12 (IL-12), G-CSF, granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 alpha (IL-1 a), interleukin-11 (IL-11), MIP-1a, leukemia inhibitory factor (LIF), c-kit ligand, thrombopoietin (TPO), CD40 ligand (CD40L), tumor necrosis factor-related activation-induced cytokine (TRANCE) and flt3 ligand (flt-3L). Cytokines are commercially available from several vendors such as, for example, Genzyme (Framingham, MA), Genentech (South San Francisco, CA), Amgen (Thousand Oaks, CA), R & D Systems and Immunex (Seattle, WA).

The sequence of many of these molecules are also available, for example, from the GenBank database. It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified cytokines (for example, recombinantly produced or mutants thereof) and nucleic acid encoding these molecules are intended to be used within the spirit and scope of the invention.

A composition which contains the nanoparticles of the invention and an adjuvant, or a vaccine or nanoparticles of the invention which is co-administered with an adjuvant, displays "enhanced immunogenicity" when it possesses a greater capacity to elicit an immune response than the immune response elicited by an equivalent amount of the vaccine administered without the adjuvant. Such enhanced immunogenicity can be determined by administering the adjuvant composition and

nanoparticle controls to animals and comparing antibody titres and/or cellular-mediated immunity between the two using standard assays such as radioimmunoassay, ELISAs, CTL assays, and the like, well known in the art.

The pharmacologically active nanoparticles may function as an adjuvant. For example they may enhance the immune response when administered with an antigen, compared to administration of the antigen alone. Thus the nanoparticles in this embodiment may be administered separately, simultaneously or sequentially with the antigen.

In the method of the invention the nanoparticles of the invention are typically delivered in liquid form or delivered in powdered form. Liquids containing the nanoparticles of the invention are typically suspensions. The nanoparticles of the invention may be administered in a liquid acceptable for delivery into an individual. Typically the liquid is a sterile buffer, for example sterile phosphate-buffered saline (PBS).

The nanoparticles of the invention are typically delivered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally or by infusion techniques. A physician will be able to determine the required route of administration for each particular patient.

The vaccine or nanoparticles are typically delivered transdermally. The term "transdermal" delivery intends intradermal (for example, into the dermis or epidermis), transdermal (for example, "percutaneous") and transmucosal administration, for example, delivery by passage of an agent into or through skin or mucosal (for example buccal, conjunctival or gum) tissue. See, for example, Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery: Fundamentals and Applications, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery of Drugs, Vols. 1- 3, Kydonieus and Berner (eds.), CRC Press, (1987).

Delivery may be via conventional needle and syringe for the liquid suspensions containing nanoparticle particulate. In addition, various liquid jet

injectors are known in the art and may be employed to administer the nanoparticles. Methods of determining the most effective means and dosages of administration are well known to those of skill in the art and will vary with the delivery vehicle, the composition of the therapy, the target cells, and the subject being treated. Single and multiple administrations can be carried out with the dose level and pattern being selected by the attending physician. The liquid compositions are administered to the subject to be treated in a manner compatible with the dosage formulation, and in an amount that will be prophylactically and/or therapeutically effective.

The nanoparticles themselves in particulate composition (for example, powder) can also be delivered transdermally to vertebrate tissue using a suitable transdermal particle delivery technique. Various particle delivery devices suitable for administering the substance of interest are known in the art, and will find use in the practice of the invention. A transdermal particle delivery system typically employs a needleless syringe to fire solid particles in controlled doses into and through intact skin and tissue. Various particle delivery devices suitable for particle-mediated delivery techniques are known in the art, and are all suited for use in the practice of the invention. Current device designs employ an explosive, electric or gaseous discharge to propel the coated core carrier particles toward target cells. The coated particles can themselves be releasably attached to a movable carrier sheet, or removably attached to a surface along which a gas stream passes, lifting the particles from the surface and accelerating them toward the target. See, for example, U.S. Patent No. 5,630,796 which describes a needleless syringe. Other needleless syringe configurations are known in the art.

Delivery of particles from such particle delivery devices is practiced with particles having an approximate size generally ranging from 0.05 to 250 μ m. The actual distance which the delivered particles will penetrate a target surface depends upon particle size (e.g., the nominal particle diameter assuming a roughly spherical particle geometry), particle density, the initial velocity at which the particle impacts the surface, and the density and kinematic viscosity of the targeted skin tissue. In this regard, optimal particle densities for use in needleless injection generally range

between about 0.1 and 25 g/cm³, preferably between about 0.9 and 1.5 g/cm³, and injection velocities generally range between about 100 and 3,000 m/sec, or greater. With appropriate gas pressure, particles can be accelerated through the nozzle at velocities approaching the supersonic speeds of a driving gas flow.

5 The powdered compositions are administered to the subject to be treated in a manner compatible with the dosage formulation, and in an amount that will be prophylactically and/or therapeutically effective.

 The pharmacologically-active nanoparticles described herein can be delivered in a therapeutically effective amount to any suitable target tissue via the above-
10 described particle delivery devices. For example, the compositions can be delivered to muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland and connective tissues.

 A "therapeutically effective amount" is defined very broadly as that amount
15 needed to give the desired biologic or pharmacologic effect. This amount will vary with the relative activity of the pharmacologically-active agent to be delivered and can be readily determined through clinical testing based on known activities of the pharmacologically-active agent being delivered. The "Physicians Desk Reference" and "Goodman and Gilman's The Pharmacological Basis of Therapeutics" are useful
20 for the purpose of determining the amount needed in the case of known pharmaceutical agents. The amount of nanoparticles administered depends on the organism (for example animal species), pharmacologically-active agent, route of administration, length of time of treatment and, in the case of animals, the weight, age and health of the animal. One skilled in the art is well aware of the dosages
25 required to treat a particular animal with a pharmacologically-active agent.

 Commonly, the nanoparticles are administered in milligram amounts, eg 1 µg to 5 mg, more typically 1 to 50 µg of pharmacologically-active agent. An appropriate effective amount can be readily determined by one of skill in the art upon reading the instant specification.

30 Mixed populations of different types of nanoparticles can be combined into

single dosage forms and can be co-administered. For example the nanoparticles may have different pharmacologically active agents adsorbed to them. The same pharmacologically-active agent can be incorporated into the different nanoparticle types that are combined in the final formulation or co-administered. Thus,
5 multiphasic delivery of the same pharmacologically-active agent can be achieved.

Below are Examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

10

Examples

In the Examples, 2-(dimethylamino)ethyl methacrylate (DMAEMA), 1-bromooctane, poly(ethylene glycol) methyl ether methacrylate ($M_n=2080$) (2), 2,2'-azobis(2-methylpropionamidine) dihydrochloride (AIBA), fluorescein and allyl
15 chloride were purchased from Aldrich. Potassium persulfate (KPS) was purchased from Carlo Erba. The poly(methacrylic acid, ethyl acrylate) 1:1 statistical copolymer (trade name Budragit® L 100-55) characterized by a number average molecular weight M_n of 250000 and the poly(butylmethacrylate, 2-dimethylamino ethyl methacrylate, methyl methacrylate) 1:2:1 statistical copolymer (trade name Budragit
20 E100) characterized by a number average molecular weight M_n of 150,000, were kindly supplied by Röhm Pharma.

All these products were used without further purification. Methyl methacrylate (MMA) was purchased from Aldrich and distilled under vacuum just before use.

25 The potentiometric titrations were conducted with a bench pH meter CyberScan pH 1000 equipped with an ATC probe and an Ingold Ag 4805-S7/120 combination silver electrode. The quaternary ammonium group amount per gram of nanoparticle was determined by potentiometric titration of the bromine ions obtained after complete ionic exchange. The ionic exchange was accomplished by dispersing
30 in a beaker 0.5 g of the nanoparticle sample in 25 ml of 1M KNO_3 at room

temperature for 48 h. In these conditions, a quantitative ionic exchange was achieved. The mixture was then adjusted to pH = 2 with dilute H₂SO₄ and the bromide ions in solution were titrated with a 0.01 M solution of AgNO₃.

The nanoparticle size was measured by a JEOL JSM-35CF scanning electron
5 microscope (SEM) with an accelerating voltage of 10-30 kV. The samples were sputter coated under vacuum with a thin layer (10-30 Å) of gold. The magnification is given by the scale on each micrograph. The SEM photographs were digitalized, using the Kodak photo-CD system, and elaborated by the NIH Image (version 1.55, public domain) image processing program. From 150 to 200 individual nanoparticle
10 diameters were measured for each optical micrograph.

Z-average particle size and polydispersity index (PI) were determined by dynamic light scattering (DLS) at 25 °C with a Zetasizer 3000 HS (Malvern, U.K.) system using a 10 mV He-Ne laser and PCS software for Windows (version 1.34, Malvern, U.K.). For the data analysis, the viscosity and refractive index of pure
15 water at 25 °C were used. The instrument was checked with a standard polystyrene latex with a diameter of 200 nm.

ζ-potential was measured at a temperature of 25 °C with a Zetasizer 3000 HS (Malvern, U.K.) and PCS software for Windows (version 1.34, Malvern, U.K.). The instrument was checked using a latexes with a known ζ-potential.

20

Reference Example 1

Synthesis of ionic monomer (1)

The ionic monomer 2-(dimethyloctyl)ammonium ethyl methacrylate bromine
(1) was obtained by direct reaction of DMAEMA with 1-bromooctane. DMAEMA
25 (0.166 mol) was mixed with 1-bromooctane (0.083 mol) without any additional solvent. After the addition of a small portion of hydroquinone to inhibit eventual radical polymerization reactions, the mixture was stirred at 50°C for 24h. The solid product so obtained was washed with dry diethyl ether to remove the excess DMAEMA. Finally, it was dried under vacuum at room temperature. The purity of
30 the product was tested by ¹H NMR spectra. Reaction yields were in the 55-65%

range.

Reference Example 2

Synthesis of fluorescent monomer (3)

- 5 2.0 g of fluorescein (6.0 mmol), 2.0 g of calcium carbonate and hydroquinone (trace) were dissolved in 100 ml of DMF, and the solution was heated at 60°C. Allyl chloride was added slowly dropwise and the reaction was allowed to proceed for 30 h in the dark. After vacuum evaporation of the solvent the product was purified by flash column chromatography (silica gel; diethyl ether-ethyl acetate 80:20 as eluent).
- 10 Yield 53%, (m.p.=123-125°C); MS, m/z (%): 412 (M⁺, 100), 371 (10), 287 (20), 259 (15), 202 (7); ¹H-NMR (CD₃OD): δ 4.44 (dd, J=5.9 and 1 Hz, 2 H, O-CH₂-CH=), 4.75 (dd, J=5.9 and 1 Hz, 2 H, O-CH₂-CH=), 5.08 (m, 2H, CH₂=CH), 5.40 (m, 2H, CH₂=CH), 5.58 (m, 1H, CH₂=CH), 6.10 (m, 1H, CH₂=CH), 6.60 (m, 2H, Ar), 6.98 (m, 3H, Ar), 7.25 (d, J=1 Hz, 1H, Ar), 7.45 (dd, J=7.5 and 1 Hz, 1H, Ar), 7.85 (m,
- 15 2H, Ar), 8.30 (dd, J=7.5 and 1Hz, 1H, Ar).

Example 1

Nanoparticle preparation

- 20 In a typical emulsion polymerization reaction, 6.0 ml (56.2 mmol) of methyl methacrylate were introduced in a flask containing 120 ml of an aqueous solution of the ionic monomer (1) obtained in Reference Example 1 and non-ionic polymer (2). The flask was fluxed with nitrogen under constant stirring for 30 min, then anionic KPS or cationic AIBA dissolved in water were added. The final amounts of initiator and comonomers in the various sample are listed in Table 1.

- 25 The flask was fluxed with nitrogen during the polymerization which was performed at 80±1.0°C for 2-4 hours under constant stirring. At the end of the reaction, the product was filtered and purified by repeated dialysis, at least ten times, against an aqueous solution of cetyl trimethyl ammonium bromide, to remove the residual methyl methacrylate, and then water, at least ten times, to remove the
- 30 residual comonomer. The nanoparticle yield, with respect to the total amount of

methyl methacrylate and of the water-soluble comonomers, was comprised between 50 and 60%.

It was found that the emulsion polymerization reaction of methyl methacrylate in the presence of specifically designed reactive surfactants and comonomers leads to monodisperse nanoparticles with a core-shell structure and a tailored surface. The inner core is mainly constituted of poly(methyl methacrylate). At the end of the reaction the water soluble units are covalently bound at the nanoparticle surface and actively participate to the latex stabilization. In this way, nanoparticles can be obtained with a tailored surface dictated by the chemical structure of the employed comonomer.

These nanoparticles were prepared by emulsion polymerization employing methyl methacrylate as the monomer, and two water-soluble comonomers, the ionic monomer (1), bearing a positively charged ammonium group, and the non-ionic polymer (2), bearing a PEG chain with number average molecular weight $M_n=2080$. Table 1 reports the composition of polymerisation reaction mixture; whereas Table 2 reports the physical characteristics of the obtained samples. Unexpectedly, these samples presented a raspberry-like morphologies, as shown in Figure 2.

To clarify the influence of the free radical initiator on the nanoparticle characteristics, in particular on the size, two different initiators were used namely, anionic KPS and cationic AIBA. Sample obtained with AIBA as free radical sources shown a mean diameter definitely lower with respect to samples obtained with KPS.

Example 2

Adsorption/release experiments

Adsorption experiments were carried out using the nanoparticles of Example 1:

DNA adsorption

For ODN adsorption experiments, 5.0 mg of freeze-dried nanospheres were suspended in 0.5 ml of 20 mM sodium phosphate buffer (pH 7.4) and sonicated for 15 min. The appropriate amount of a concentrated aqueous solution of ODN was

- then added to reach the final concentration (10–200 μ M). Several oligomers (18 mer to 22 mer) were tested and the interaction with the nanoparticles was found to be not sequence specific. The experiments were run in triplicate ($SD \leq 10\%$). The suspensions were continuously stirred at 25°C for 48 h. After centrifugation at about 8000 rpm for 5 min, quantitative sedimentation of the ODN-nanoparticle complex was obtained and aliquots (10–50 μ l) of the supernatant were withdrawn, filtered on a Millex GV₄ filter unit and diluted with sodium phosphate buffer. Finally, UV absorbance at $\lambda = 260$ nm was measured. Adsorption efficiency (%) was calculated as $100 \times (\text{administered ODN}) - (\text{unbound ODN}) / (\text{administered ODN})$.
- 10 Similarly, DNA adsorption experiments were run by adding the appropriate amount of a concentrated aqueous solution of DNA to reach the final concentration (10–250 μ g/ml). Again adsorption of plasmid DNA was found to be not sequence specific.

DNA release

- 15 The nanosphere samples (5.0 mg / 0.5 ml) were charged with the appropriate amount of ODN and DNA. Release was monitored after 2 h at room temperature in the presence of various NaCl concentration phosphate buffers (20 mM, pH 7.4) through direct measurement of released DNA absorbance ($\lambda = 260$ nm). The experiments were run in triplicate ($SD \leq 10\%$).

- 20 Adsorption experiments using the nanoparticles of Example 1 in the presence of model oligo(deoxy) nucleotides (ODN) showed a similar behaviour for PEG1, PEG2, PEG3 and PEG4 (Figure 3).

- PEG3, the smallest nanoparticle sample obtained, was selected for further characterization. To this purpose, its preparation was repeated on a large scale synthesis, thus leading to samples PEG32 (total volume = 500 ml). After physico-chemical characterization, ODN and DNA adsorption/release experiments were run. It was found that these nanoparticles are able to bind relatively high amounts of plasmid PCV₀ – tat DNA (5–6% w/w) and release them with distinct kinetic pathways (Figures 4–6).
- 25

Table 1. Composition of emulsion polymerization reaction mixture (total volume: 126 ml). *large scale synthesis (total volume = 500ml)

| | | | | | | |
|----|------------|--------------------------|---------------------|-----------------------------|---------------------|-----------------------------|
| 5 | Sample | Comonomer 1 (mmol) | Polymer 2 (mmol) | Comonomer 3 (μ mol) | Initiator (mmol) | Reaction time (hours) |
| | PEG1 | 3.00 | 0.14 | | KPS 0.22 | 2 |
| 10 | PEG2 | 3.00 | 0.31 | | KPS 0.22 | 2 |
| | PEG3 | 3.00 | 0.52 | | KPS 0.22 | 2 |
| 15 | PEG3 fluo* | 12.50 | 2.16 | 48.0 | KPS 0.92 | 2 |
| | PEG4 | 3.00 | 0.70 | | KPS 0.22 | 2 |
| 20 | PEG32* | 12.50 | 2.16 | | KPS 0.92 | 2 |
| | Z2 | 3.60 | 0.52 | | AIBA 0.092 | 4 |
| | Z2fluo* | 15.0 | 2.13 | 18.9 | AIBA 0.38 | 4 |
| 25 | Z3 | 3.60 | 0.78 | | AIBA 0.092 | 4 |

Table 2. Nanoparticle physico-chemical characterization

| | Sample | SEM diameter (nm) | PCS diameter (nm) | Zp (mV) | Surface charge density ($\mu\text{mol m}^{-2}$) |
|----|-----------|----------------------|----------------------|-----------------|--|
| 5 | PEG1 | 930 ± 290 | / | / | 27.5 |
| | PEG2 | 890 ± 140 | / | / | 2.24 |
| 10 | PEG3 | 550 ± 200 | 469.0 ± 3.5 | $+34.7 \pm 0.3$ | 6.66 |
| | PEG3 fluo | 627 ± 38 | 663.8 ± 38.09 | $+16.6 \pm 0.6$ | 10.9 |
| | PEG4 | 460 ± 60 | / | / | 2.08. |
| 15 | PEG32 | 960 ± 38 | 923.6 ± 3.9 | $+32.2 \pm 0.6$ | 2.16 |
| | Z2 | 180 ± 18 | 218 ± 60 | $+17.7 \pm 1.2$ | 6.35 |
| 20 | Z3 | 136 ± 13 | 160 ± 61 | $+9.9 \pm 1.2$ | 2.63 |
| | Z2fluo | / | 204.3 ± 0.5 | $+17.6 \pm 0.9$ | / |

Example 3

Nanoparticle preparation

In a typical emulsion polymerization reaction, the appropriate amount of Eudragit® L100-55 was introduced in a flask containing 200 ml of water or a mixture water/acetone 90/10 vol% (see Table 3) adjusted at pH 8.0 with NaOH. The flask was fluxed with nitrogen under constant stirring then 25.0 ml (234 mmol) of MMA were added dropwise. The system was let to stabilize for 20 min, then 21.0 mg (77.7 μ mol) of KPS dissolved in 2 ml of water were added. The polymerization was performed at $70 \pm 1.0^\circ\text{C}$ for 17h. At the end of the reaction, the product was filtered and purified by repeated dialysis against water. The nanoparticle yield, with respect to the methyl methacrylate was comprised between 75 and 90%. A fluorescent nanoparticle sample was prepared in a large scale synthesis: 7.5 g of Eudragit® L100-55 was introduced in a 1L five-neck reactor containing 500 ml of water (see Table 3) adjusted at pH 8.0 with NaOH. The reactor was fluxed with nitrogen under constant stirring then 39 mg of the fluorescent monomer (3) obtained in Reference Example 2 dissolved in 62.0 ml (580 mmol) of MMA were added dropwise. The system was let to stabilize for 20 min, then 52.5 mg (194 μ mol) of KPS dissolved in 3 ml of water were added. The polymerization was performed at $70 \pm 1.0^\circ\text{C}$ for 17h. At the end of the reaction, the product was purified as previously described.

As a typical example, a SEM micrograph of sample M1 is reported in Figure 7 whereas Table 3 collects some physicochemical characteristics of the samples including the number average diameter calculated by SEM and PCS. In addition, the ζ -Potential values are reported. The size of the nanoparticles is small, ranging from 120 to 140 nm. The size of the nanoparticles increases in water, as can be observed from the comparison of the diameters from SEM and PCS, due to the presence of the Eudragit® L 100/55 at the surface in agreement with their core-shell nature. This result is also supported by the negative ζ -Potential values due to the presence of negatively charged carboxylic groups of the stabilizer.

Thus polymethylmethacrylate core-shell particles in the nanometre scale range can be prepared by emulsion polymerization. The nature of the outer layer is dictated by the stabilizer Eudragit® L 100/55 which affords:

- i) steric stabilization to the latex;
- 5 ii) a hydrophilic outer layer deriving able to decrease the particle capture by RES and to influence the particle biodistribution; and
- iii) carboxyl groups able to interact with Tat via specific or non specific interactions.

10 Example 4

In a typical emulsion polymerization reaction, 2.0 g of Eudragit E 100 were introduced in a 1L five-neck reactor containing 500 ml of water adjusted at pH 3.0 with HCl. The reactor was fluxed with nitrogen under constant stirring then 75.0 ml
15 (702 mmol) of MMA were added dropwise. The system was let to stabilize for 20 min, then 62.0 mg (229 μ mol) of KPS dissolved in 3 ml of water were added. The polymerization was performed at 70"1.0°C for 17h. At the end of the reaction, the product was purified as described in example 3. Sample MC3 was obtained with a diameter of 67 nm.

Table 3. Amount of monomer (MMA), and stabilizer (Eudragit® L100-55), reaction medium composition, number average diameter as determined by SEM analysis (D_{SEM}), average diameter as determined by PCS analysis (D_{PCS}), and ζ -Potential for samples M1-M4.

5

| Sample | MMA mmol | Eudragit® L100-55 g | Reaction medium | D_{SEM} nm | D_{PCS} nm | ζ -Potential mV |
|------------|-------------|---------------------------|-----------------------------|-----------------|-----------------|--------------------------|
| M1 | 234.0 | 1.00 | water | 136 | 197 | -45.4 |
| M2 | 234.0 | 2.00 | water | 128 | 188 | -45 |
| M3 | 234.0 | 3.00 | water | 136 | 182 | -46 |
| M4 | 234.0 | 2.00 | water/acetone 90/10 vol% | 140 | 213 | -45.7 |
| M2 fluo | 580.0 | 7.4 | water | / | 154 | -52.9 |

10

CLAIMS


1. Core-shell nanoparticles comprising:

(a) a core which comprises a water insoluble polymer or copolymer, and

(b) a shell which comprises a hydrophilic polymer or copolymer;

said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble styrenic, acrylic or methacrylic monomer and:

(i) a monomer of formula (I):




wherein

R¹ represents hydrogen or methyl, and

R² represents -COOAH, -COO-A-NR⁹R¹⁰ or -COO-A-N⁺R⁹R¹⁰R¹¹ X⁻, in which A represents C₁₋₂₀ alkylene, R⁹, R¹⁰ and R¹¹ each independently represent hydrogen or C₁₋

alkyl and X represents halogen, sulphate, sulphonate or perchlorate, and a water-soluble polymer of formula (II)



wherein


R³ represents hydrogen or methyl,

R⁴ represents hydrogen or C₁₋₂₀ alkyl, and


n is an integer such that the polymer of formula (I) has a number-average molecular weight of at least 1000; or

(ii) a hydrophilic copolymer which comprises repeating units of formulae (III) and (IV):

5



10



wherein

15 R⁵ and R⁷ each independently represent hydrogen or methyl,
R⁶ represents hydrogen, -A-NR⁹R¹⁰ or -A-N⁺R⁹R¹⁰R¹¹ X⁻, in which A represents C₁₋₂₀ alkylene, R⁹, R¹⁰ and R¹¹ each independently represent hydrogen or C₁₋₂₀ alkyl and X represents halogen, sulphate, sulphonate or perchlorate and
R⁸ represents C₁₋₁₀ alkyl.

20 2. Nanoparticles according to claim 1 wherein the core comprises poly(C₁₋₁₀ alkyl (meth)acrylate), polystyrene or a copolymer formed from monomers which are acrylic, methacrylic or styrenic monomers.

3. Nanoparticles according to claim 1 or 2 wherein the core comprises poly(methyl methacrylate).

25 4. Nanoparticles according to any one of claims 1 to 3 which are obtainable by emulsion polymerization of methyl methacrylate in an aqueous solution comprising poly(ethylene glycol) methyl ether methacrylate and 2-(dimethyloctyl) ammonium ethyl methacrylate bromine.

5. Nanoparticles according to any one of claims 1 to 3 which are obtainable by emulsion polymerization of methyl methacrylate in an aqueous solution comprising a copolymer of methacrylic acid and ethyl acrylate.
6. Nanoparticles according to any one of claims 1 to 3 which are obtainable by emulsion polymerization of methyl methacrylate in an aqueous solution comprising a copolymer of 2-(dimethylamino)ethyl methacrylate and C₁₋₆ alkyl methacrylate.
7. Nanoparticles according to any one of the preceding claims which have a number-average particle diameter measured by scanning electron microscopy of from 50 to 1000 nm.
8. Nanoparticles according to any one of the preceding claims which further comprise a fluorescent chromophore.
9. A process for preparing nanoparticles according to any one of the preceding claims, said process comprising emulsion polymerization of a water-insoluble monomer in an aqueous solution comprising:
 - (i) a monomer of formula (I) and a polymer of formula (II), or
 - (ii) a hydrophilic copolymer which comprises repeating units of formulae (III) and (IV).
10. Nanoparticles according to any one of claims 1 to 8 which further comprise at least one pharmacologically active agent adsorbed at the surface of the nanoparticles.
11. Nanoparticles according to claim 10 wherein the pharmacologically active agent is a disease-associated antigen.
12. Nanoparticles according to claim 11 wherein the antigen is a deoxyribonucleic acid, ribonucleic acid, oligodeoxynucleotide, oligonucleotide or protein.
13. Nanoparticles according to claim 11 or 12 wherein the antigen is a microbial antigen or a cancer-associated antigen.
14. Nanoparticles according to any one of claims 11 to 13 wherein the antigen is a human immunodeficiency virus-1 (HIV-1) antigen.

15. Nanoparticles according to claim 14 wherein the antigen is HIV-1 Tat protein or an immunogenic fragment thereof.
16. A process for preparing nanoparticles according to any one of claims 10 to 15, said process comprising adsorbing a pharmacologically active agent at the surface
5 of nanoparticles according to any one of claims 1 to 8.
17. A pharmaceutical composition comprising nanoparticles according to any one of claims 10 to 15 and a pharmaceutically acceptable excipient.
18. A method of diagnosing, treating or preventing a condition in a subject said method comprising administering an effective amount of nanoparticles according to
10 any one of claims 10 to 15 or a pharmaceutical composition according to claim 17 to a subject in need of such treatment.
19. A method of generating an immune response in a subject, said method comprising administering nanoparticles according to any one of claims 11 to 15 in a therapeutically effective amount.
- 15 20. A method of preventing or treating HIV infection or AIDS, said method comprising administering nanoparticles according to any one of claims 11 to 15 in a therapeutically effective amount.
21. Nanoparticles according to any one of claims 10 to 15 or a pharmaceutical composition according to claim 17 for use in a method of treatment of the human or
20 animal body by therapy or a diagnostic method practised on the human or animal body.
22. Use of nanoparticles according to any one of claims 10 to 15 for the manufacture of a medicament for diagnosing, treating or preventing a condition in a subject.
- 25 23. Use of nanoparticles according to any one of claims 10 to 15 for the manufacture of a medicament for preventing or treating HIV infection or AIDS.

ABSTRACT
NANOPARTICLES FOR DELIVERY OF A PHARMACOLOGICALLY
ACTIVE AGENT


Core-shell nanoparticles comprising:

- 5 (a) a core which comprises a water insoluble polymer or copolymer, and
 (b) a shell which comprises a hydrophilic polymer or copolymer;

said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble styrenic, acrylic or methacrylic monomer and:

10

- (i) a monomer of formula (I):




15

wherein

R¹ represents hydrogen or methyl, and

- R² represents -COOAH, -COO-A-NR⁹R¹⁰ or -COO-A-N⁺R⁹R¹⁰R¹¹ X⁻, in which A
20 represents C₁₋₂₀ alkylene, R⁹, R¹⁰ and R¹¹ each independently represent hydrogen or C₁₋₂₀
20 alkyl and X represents halogen, sulphate, sulphonate or perchlorate, and
a water-soluble polymer of formula (II)

25



wherein


R³ represents hydrogen or methyl,

- 30 R⁴ represents hydrogen or C₁₋₂₀ alkyl, and


n is an integer such that the polymer of formula (I) has a number-average molecular weight of at least 1000; or

(ii) a hydrophilic copolymer which comprises repeating units of formulae (III) and (IV):

5




10



wherein

- 15 R⁵ and R⁷ each independently represent hydrogen or methyl,
 R⁶ represents hydrogen, -A-NR⁹R¹⁰ or -A-N⁺R⁹R¹⁰R¹¹ X⁻, in which A represents C₁₋₂₀
 alkylene, R⁹, R¹⁰ and R¹¹ each independently represent hydrogen or C₁₋₂₀ alkyl and X
 represents halogen, sulphate, sulphonate or perchlorate and
 R⁸ represents C₁₋₁₀ alkyl.

Figure 1



Core-wide corona

2/7

Figure 2




Figure 3

Adsorbed ODN (%)



Adsorbed ODN
($\mu\text{mol/g}$)

Figure 4





Figure 5






Figure 6



7/7

Figure 7



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.